Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

16.08.24	Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age (Businesswire)
12.08.24	Pfizer's RSV Vaccine ABRYSVO Shows Positive Results In Phase 3 Study In Immunocompromised Adults (RTTNews)
12.08.24	Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults (Businesswire)
04.08.24	Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid (RTTNews)
31.07.24	ViiV Healthcare Reports Positive Data For 2-Drug Regimen DOVATO In HIV-1 Treatment (RTTNews)
30.07.24	Pfizer Boost FY24 Outlook - Update (RTTNews)
30.07.24	Pfizer Inc. Q2 Profit Decreases, But Beats Estimates (RTTNews)
30.07.24	Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance (Businesswire)
25.07.24	Pfizer Gets EC's Conditional Authorization For Durveqtix Genetherapy In Hemophilia B (RTTNews)
25.07.24	European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B (Businesswire)
24.07.24	Pfizer's Phase 3 AFFINE Study Of Hemophilia A Gene Therapy Candidate Meets Primary Goal (RTTNews)
24.07.24	Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate (Businesswire)
11.07.24	Pfizer Advances Once-Daily Formulation Of Oral GLP-1 Receptor Agonist Danuglipron (RTTNews)
11.07.24	Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron (Businesswire)
09.07.24	Pfizer Chief Scientific Officer Mikael Dolsten To Step Down (RTTNews)
09.07.24	Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development (Businesswire)
03.07.24	GSK Acquires Global Rights For MRNA Vaccines For Influenza & COVID-19 In CureVac Deal - Quick Facts (RTTNews)
01.07.24	Cyrus Taraporevala Elected to Pfizer’s Board of Directors (Businesswire)
27.06.24	Pfizer, BioNTech Get CHMP's Positive Opinion For Marketing Authorization Of Omicron JN.1 Vaccine (RTTNews)
27.06.24	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union (Businesswire)
26.06.24	Pfizer Declares Third-Quarter 2024 Dividend (Businesswire)
18.06.24	Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts (Businesswire)
14.06.24	ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma (Businesswire)
13.06.24	Pfizer's Phase 3 Duchenne Gene Therapy Trial Fails To Meet Primary And Secondary Endpoints (RTTNews)
12.06.24	Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy (Businesswire)
03.06.24	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
01.06.24	Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/?Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Businesswire)
31.05.24	Pfizer's Phase 3 Crown Trial Of Lobrena Reports 5-year Non-progression Results In NSCLC Patients (RTTNews)
31.05.24	Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression (Businesswire)
23.05.24	Pfizer's Hospira Recalls Select Hydrochloride Injection Carpuject Units (RTTNews)
16.05.24	Arvinas, Pfizer, Report 6-month Follow Up Data From Phase 1b Study Of Vepdegestrant+Palbociclib (RTTNews)
13.05.24	Amazon, Microsoft, Pfizer To Invest Billions In French Projects (RTTNews)
06.05.24	Andrew Baum To Oversee Pfizer's Innovation, Portfolio Strategy (RTTNews)
06.05.24	Pfizer Announces New Chief Strategy and Innovation Officer (Businesswire)
01.05.24	Pfizer Boost FY24 Adj. EPS Outlook - Update (RTTNews)
01.05.24	Pfizer Inc. Q1 Profit Decreases, but beats estimates (RTTNews)
01.05.24	Pfizer Reports First-Quarter 2024 Results (Businesswire)
30.04.24	Biotech Stocks Facing FDA Decision In May 2024 (RTTNews)
30.04.24	Pfizer,Genmab: FDA Grants Full Approval For TIVDAK To Treat Recurrent Or Metastatic Cervical Cancer (RTTNews)
30.04.24	FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer (Businesswire)
29.04.24	Labcorp: FDA Approves NAbCyte Companion Diagnostic - Quick Facts (RTTNews)
29.04.24	Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting (Businesswire)
26.04.24	Pfizer's Beqvez Receives FDA Approval For Treatment Of Adults With Hemophilia B (RTTNews)
26.04.24	U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B (Businesswire)
24.04.24	Pfizer Declares Second-Quarter 2024 Dividend (Businesswire)
22.04.24	Pfizer's Emblaveo Gets EU Marketing Authorization For Serious Infectious Disease (RTTNews)
22.04.24	European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options (Businesswire)
11.04.24	Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25 (Businesswire)
09.04.24	Pfizer Reports Positive Results From Phase 3 Abrysvo Vaccine Study (RTTNews)
09.04.24	Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

17.12.24		Schwacher Handel in New York: Dow Jones schliesst im Minus
17.12.24		Schwacher Handel in New York: NASDAQ Composite legt schlussendlich den Rückwärtsgang ein
17.12.24		Schwache Performance in New York: S&P 500 beendet den Handel im Minus
17.12.24		Pfizer-Aktie unverändert: Umsatz auf Vorjahreshöhe für 2025 geplant
17.12.24		Dow Jones-Handel aktuell: Dow Jones mit Abgaben
17.12.24		Anleger in New York halten sich zurück: S&P 500 präsentiert sich nachmittags leichter
17.12.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite notiert nachmittags im Minus
17.12.24		Minuszeichen in New York: Dow Jones am Mittag schwächer

17.12.24

Schwacher Handel in New York: Dow Jones schliesst im Minus

17.12.24

Schwacher Handel in New York: NASDAQ Composite legt schlussendlich den Rückwärtsgang ein

17.12.24

Schwache Performance in New York: S&P 500 beendet den Handel im Minus

17.12.24

Pfizer-Aktie unverändert: Umsatz auf Vorjahreshöhe für 2025 geplant

17.12.24

Dow Jones-Handel aktuell: Dow Jones mit Abgaben

17.12.24

Anleger in New York halten sich zurück: S&P 500 präsentiert sich nachmittags leichter

17.12.24

NASDAQ Composite-Handel aktuell: NASDAQ Composite notiert nachmittags im Minus

17.12.24

Minuszeichen in New York: Dow Jones am Mittag schwächer

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	137.35	1.40 %	K V
Sonova Hldg	297.30	1.29 %	K V
Logitech Intl	74.86	1.22 %	K V
Nestle	75.22	1.02 %	K V
Alcon	76.32	0.95 %	K V
UBS Group	28.17	-0.67 %	K V
Swiss Re	131.95	-0.68 %	K V
Geberit	533.80	-0.78 %	K V
Lonza Grp	541.40	-0.81 %	K V
Kuehne+Nagel Int	202.60	-1.65 %	K V

Nachrichten zu Pfizer Inc.

Aktien Top/Flop

Pfizer Peer Group Nachrichten

Meistgelesene Nachrichten